The global insulin delivery devices market is poised for robust expansion, projected to grow from USD 35.3 billion in 2025 to USD 52.7 billion by 2030, at a CAGR of 8.3%. This sustained growth reflects a rising global diabetes burden and the rapid evolution of delivery technologies that are transforming how patients manage their condition.
Market Overview
The insulin delivery devices market is experiencing dynamic transformation, driven primarily by the increasing prevalence of type 1 and type 2 diabetes, coupled with aging populations and lifestyle-related diseases such as obesity. As the number of individuals requiring long-term insulin therapy grows, demand for efficient, user-friendly, and smart delivery solutions—including insulin pens, pumps, and patch systems—continues to surge.
Rising healthcare expenditures in diabetes management and ongoing advancements in drug delivery technology are fueling market opportunities. Strategic partnerships and R&D investments among leading manufacturers are enabling the development of next-generation insulin devices designed to improve adherence, reduce errors, and enhance patient comfort.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092
Market Growth Drivers
-
Rising Global Diabetes Burden – The sharp increase in diabetes prevalence worldwide remains the key market driver, particularly in developing economies.
-
Technological Innovation – Integration of smart pens, continuous glucose monitoring (CGM) systems, and automated insulin delivery (AID) technologies are revolutionizing patient care.
-
Growing Healthcare Expenditure – Governments and private insurers are prioritizing diabetes management, creating favorable conditions for advanced device adoption.
-
Strategic Collaborations and M&A Activity – Partnerships between device makers, software developers, and biotech firms are accelerating product innovation and global expansion.
Together, these forces are reshaping the insulin delivery landscape, making treatment more precise, connected, and patient-friendly.
Key Market Players and Strategic Highlights
The insulin delivery devices market is moderately consolidated, with leading companies employing a mix of organic and inorganic strategies—including acquisitions, product launches, regulatory approvals, and capacity expansions—to strengthen their market presence.
1. Novo Nordisk A/S (Denmark): Pioneering Intelligent Insulin Delivery
Novo Nordisk remains at the forefront of diabetes care, leveraging its deep expertise in insulin and GLP-1 analogs alongside innovative delivery systems. The company’s recent milestones include:
-
Jan 2025: Launch of Awiqli (insulin icodec injection) in Japan, delivered via its prefilled FlexTouch pen, marking another step in simplifying diabetes management.
-
Dec 2024: Acquisition of three manufacturing facilities from Novo Holdings A/S (after Novo Holdings’ acquisition of Catalent, Inc.), expanding Novo Nordisk’s production capabilities and global reach.
-
May 2024: EMA approval for Awiqli (insulin icodec) — a once-weekly insulin, a groundbreaking innovation for patient convenience.
With a presence in over 170 markets, Novo Nordisk continues to invest in connected drug delivery, evidenced by its 2023 acquisition of BIOCORP Production SA (France) to strengthen smart pen and digital health integration. Products like NovoPen 6 exemplify its push toward real-time data-driven diabetes care.
2. Embecta Corp. (US): A Global Leader in Injection-Based Delivery
Spun off from Becton, Dickinson and Company (BD) in April 2022, Embecta is the largest manufacturer of insulin syringes and pen needles, producing around 6 billion pen needles and 1.5 billion syringes annually. Operating in over 100 countries, Embecta continues to lead the injection-based delivery segment.
-
May 2023: Partnered with Tidepool (US) to co-develop an automated insulin delivery (AID) system for type 2 diabetes.
-
Secured exclusive or dual-preferred brand status with major Medicare Part D payers in the US, reinforcing its leadership in accessibility and affordability.
Embecta’s strategic collaborations and strong manufacturing base position it as a key player in advancing closed-loop insulin delivery systems and expanding patient-centric diabetes care.
3. Medtronic Plc (Ireland), Sanofi (France), and Eli Lilly and Company (US): Driving Smart Delivery Innovation
Other global leaders—Medtronic, Sanofi, and Eli Lilly—continue to strengthen their presence through R&D and portfolio diversification.
-
Medtronic focuses on integrated insulin pumps and glucose monitoring systems, pioneering hybrid closed-loop technologies.
-
Sanofi and Eli Lilly are recognized for their innovative insulin pen portfolios and partnerships in connected delivery ecosystems, aiming to enhance user experience and precision dosing.
Market Structure and Competitive Landscape
Based on market share analysis and product portfolio breadth, five key players—Embecta Corp., Novo Nordisk A/S, Medtronic Plc, Sanofi, and Eli Lilly—collectively account for 25–50% of the total market share. The remaining share is distributed among numerous regional and emerging players, contributing to a fragmented yet highly competitive market.
Smaller companies and startups are seizing opportunities by offering affordable insulin pens, patch pumps, and connected device innovations, fostering technological diversity and competition in the global market.
The Future of Insulin Delivery Devices
The next wave of growth in the insulin delivery market will be defined by digitalization, automation, and patient empowerment. The convergence of AI-driven dose algorithms, smart connectivity, and wearable devices will reshape diabetes management from reactive care to proactive control.
As leading manufacturers continue to innovate and collaborate, the global insulin delivery devices market is set to play a transformative role in enhancing patient outcomes, improving adherence, and redefining convenience in diabetes care.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092